HOWL
Werewolf Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$48.60M
P/E Ratio
—
EPS
$-1.33
Beta
0.54
52W High
$2.38
52W Low
$0.53
50-Day MA
$0.73
200-Day MA
$1.10
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-41.73M |
| EBITDA | $-59.04M |
| Operating Margin | 0.00% |
| Return on Equity | -123.90% |
| Return on Assets | -38.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.51 |
| Price-to-Book | 1.95 |
| Price-to-Sales (TTM) | 10.21 |
| EV/Revenue | 0.674 |
| EV/EBITDA | 0.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $48.60M |
| Float | $41.23M |
| % Insiders | 5.62% |
| % Institutions | 41.14% |
Analyst Ratings
Consensus ($7.00 target)
4
Buy1
HoldData last updated: 4/8/2026